Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies Aug 2, 2022 06:30AM
Xencor (XNCR) Sells Exclusive Worldwide Rights to Obexelimab to Zenas BioPharma Nov 22, 2021 05:42AM
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor Nov 21, 2021 06:00PM
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor Nov 21, 2021 06:00PM
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor Nov 21, 2021 06:00PM


Mar 23, 2021 04:00AM Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
Mar 23, 2021 04:00AM Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
Mar 23, 2021 04:00AM Lancement de Zenas BioPharma, société biopharmaceutique transfrontalière qui innove dans le développement et la fourniture de traitements immunitaires
Feb 26, 2018 08:00AM Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates
Nov 3, 2016 08:00AM Selexis and Xencor Enter Strategic Agreement, Strengthening Existing Relationship for Multi-Specific Antibody Cell Line Development
Oct 14, 2016 08:30AM Cancer Immunotherapy ETF Celebrates One-Year Anniversary
Dec 16, 2015 07:00AM Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
Sep 16, 2015 07:30AM Amgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And Inflammation